Abstract
Classic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment of HL has evolved drastically based on the advent of novel targeted therapies. Novel agents including programmed death-1 (PD-1) inhibitors, antibody-drug conjugates such as brentuximab vedotin, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapies have served to shape the management of HL in the frontline as well as the relapsed and refractory (R/R) setting. Some of these agents have been incorporated into treatment algorithms, while others are currently under investigation demonstrating promising results. This review focuses on highlighting the underlying tumor biology forming the basis of therapeutics in HL, and reviews some of the emerging and established novel therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 705-713 |
Number of pages | 9 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 23 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2023 |
Keywords
- Hodgkin lymphoma
- Lymphoid malignancies
- Novel therapies
- Targeted therapies
- Tumor immune microenvironment
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research